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Abstract
Background Neuropathic pain is a chronic pain state that negatively impacts the quality of life. Currently, available therapies 
for the treatment of neuropathic pain often lack efficacy and tolerability. Therefore, the search for novel drugs is crucial to 
obtain treatments that effectively suppress neuropathic pain.
Objectives The present study was undertaken to investigate the antinociceptive properties of (1,4-bis-(diphenylphosphino) 
butane) palladium (II) chloride monohydrate (Compound 1) in a paclitaxel (PTX)-induced neuropathic pain model.
Methods Initially, behavioral tests such as mechanical and cold allodynia as well as thermal and tail immersion hyperalgesia 
were performed to investigate the antinociceptive potential of Compound 1 (5 and 10 mg/kg, b.w). RT-PCR was performed 
to determine the effect of Compound 1 on the mRNA expression level of inducible nitric oxide synthase (iNOS), cyclooxy-
genase-2 (COX-2), and proinflammatory cytokines such as tumor necrosis factor-alpha (TNF)-α, interleukin (IL)-1β, and 
IL-6. In addition, antioxidant protein, nitric oxide (NO), and malondialdehyde (MDA) levels were also determined.
Results The results demonstrated that once-daily dosing of Compound 1 significantly suppressed the PTX-induced behav-
ioral pain responses dose-dependently. The mRNA gene expressions of iNOS, COX-2, and inflammatory cytokines were 
markedly reduced by Compound 1. Furthermore, it enhanced the level of antioxidant enzymes and lowered the level of MDA 
and NO production.
Conclusion These findings suggest that the antinociceptive potential of Compound 1 in the PTX-induced neuropathic pain 
model is via suppression of oxidative stress and inflammation. Thus, Compound 1 might be a potential candidate for the 
therapeutic management of PTX induced neuropathic pain.
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Introduction
Neuropathic pain occurs due to the damage of peripheral or 
central nerves [1, 2]. It is generally characterized by extreme 
sensitivity to non-noxious stimuli (allodynia) and noxious 
stimuli (hyperalgesia). Neuropathic pain arises due to trauma, 
disease, and chemotherapeutic drugs [2, 3]. Macrophages are a 
vital component of the immune system and play pivotal roles in 
the regulation of inflammatory responses [4]. Macrophages are 
implicated in the pathogenesis of neuropathic pain [5]. Follow-
ing nerve injury, resident macrophages initiate inflammatory 
responses and elicit long-lasting neuroinflammation through 
the recruitment of circulating leukocytes to the site of injury 
[4]. At the periphery, activated macrophages secrete cytokines/
chemokines such as TNF-α (tumor necrosis factor-α) and 
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interleukins (IL-1β, IL-6). Cytokines and chemokines secreted 
by macrophages are potential mediators of pain hypersensitiv-
ity in neuropathic pain [5]. Paclitaxel (PTX) is a well-known 
chemotherapeutic agent that is widely used for the treatment 
of breast, ovarian, lung, and bladder cancers [6]. However, 
treatment with PTX may result in peripheral neuropathy that 
exists for several months even after discontinuation of therapy 
[7]. Peripheral neuropathy is a major reason for reduction of 
dose or even cessation of chemotherapy and therefore, results 
in a great impact on the survival of cancer patients [8].
Numerous studies have revealed that inflammatory 
responses in the spinal cord result in the development of 
chemotherapy-induced peripheral neuropathy [9, 10]. It 
is well recognized that pro-inflammatory mediators are 
released by activated glial cells in the spinal cord which 
intensifies the sensitivity and excitability of the neuron [11]. 
Several lines of evidence have indicated that COX-2 (an 
inducible enzyme) and iNOS are associated with the induc-
tion and progression of neuropathic pain [12]. Peripheral 
nerve injury elevates the expression of COX-2 in the spinal 
cord which facilitates inflammation and pain hypersensitiv-
ity [13]. In addition, oxidative stress plays a crucial role in 
the pathogenesis of neuropathic pain [14].
Currently, treatment for neuropathic pain includes 
NSAIDs, morphine, anti-convulsant, and anti-depressants 
drug. However, these treatments have been associated with 
a wide spectrum of adverse effects [2]. The compounds 
containing structural palladium thiocarbamate have been 
reported for various anti-inflammatory and analgesic prop-
erties [15]. Pronounced pharmacological effects with a better 
safety profile have been considered by designing and syn-
thesizing palladium-containing complexes [16]. The dithi-
ocarbamates have also been reported for promising activi-
ties against oxidative stress and inflammatory cytokine [17]. 
It has been noted that dithiocarbamates structural analogs 
exhibit antiarthritic activities via inhibition of NF‐κB and 
COX-2 signaling [18]. The characterization of Compound 
1 has recognized it to be an efficient drug moiety. Earlier 
results have indicated that Compound 1 has suppressed the 
complete Freund's adjuvant (CFA)-, carrageenan-, hista-
mine-, and serotonin-induced nociception [19]. Thus, bear-
ing in mind the above-mentioned results, we decided to fur-
ther explore the neuroprotective property of Compound 1 
against PTX-induced neuropathic pain model.
Materials and methods
Chemicals and reagents
The DNA Extraction Kit (Novel Genomic DNA Mini Kit), 
TRI-Reagent (Bioshop, Canada), cDNA Synthesis Kit 
(ABM, Canada), PCR Primers (Macrogen Korea), PCR 
Master Mix (Thermo Fisher Scientific US). PTX, Compound 
1, gabapentin (GBP), Griess Reagent, 1-chloro-2,4-dini-
trobenzene (CDNB), dithio-nitrobenzoic acid (DTNB), 
hydrogen peroxide (H2O2), and all the other chemicals used 
were obtained from Sigma (USA). Drugs were dissolved in 
dimethyl sulfoxide (DMSO 2%) and diluted with normal 
saline up to the final volume.
Synthesis of compound 1
Compound 1 (1,4-bis-(diphenylphosphino) butane) pal-
ladium (II)chloride monohydrate) was synthesized 
according to the literature procedure [19]. Briefly, it was 
prepared by simultaneous and dropwise addition of 1,4-bis-
(diphenylphosphino) butane (0.426 g, 1 mmol) in acetone 
(40 mL) and sodium 4-benzylpiperidine-1-carbodithioate 
(0.273 g, 1 mmol) in methanol (25 mL) to a methanolic 
suspension of palladium (II) chloride (0.177 g, 1 mmol). The 
reaction mixture was refluxed for 6 h with constant stirring. 
It was then filtered, and the filtrate was rotary evaporated. 
The product was soluble in acetone, chloroform, methanol, 
and dimethylsulfoxide.
Animals and experimental design
Sprague–Dawley female rats (200–250 g) were used in the 
present study. The animals were obtained from the NIH 
Islamabad, Pakistan. All the rats were accommodated in 
standard environmental conditions (22 ± 1 ºC, 52 ± 3% 
humidity) and a light/dark period of 12-h with unrestricted 
access to food and water.
Induction of neuropathic pain and dosing
PTX (4 mg/kg) was injected intraperitoneally (i.p.) in vol-
umes of 1 ml per kg, 4 times a week (on days 1, 3, 5, and 
7) [20]. PTX dose selection was selected based on a previ-
ous report [20]. Compound 1 (5 and 10 mg) was admin-
istered once daily for 8 days. The doses of Compound 1 
were selected based on its previously reported therapeutic 
activities in animal models of arthritis [19]. Previously, in 
the first set of experiments, different doses of Compound 
1 were screened to select an optimum and effective dose. 
Compound 1 was tested at a dose level of 0.1, 1, and 10 mg/
kg. It exhibited optimum anti-inflammatory and analgesic 
effects at the doses of 5 and 10 mg/kg of body weight in 
mice [19]. The schedule of behavioral experimentations was 
on day 0 i.e., before first drug administration and then on 
every other day of PTX administration i.e., on days 2, 4, 6, 
and 8 after 1 h of treatment. Samples were collected after 
all the rats were sacrificed from each group on the final day 
of the experiment (Fig. 1).
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Animal’s models
Compound 1 was tested in a PTX-induced neuropathic 
pain model. All the animals were allotted in normal, nega-
tive (PTX-induced), positive (GBP) and treatment groups 
(5 and 10 mg/kg of Compound 1) with 6 animals in each 
group. Behavioral testing was carried out by an experimenter 
blinded to the treatment groups.
PTX‑induced model
Rats were distributed into five groups with six rats per 
group:
Group 1: Normal control.
Group 2: PTX-induced (4 mg/kg, i.p).
Group 3: GBP 75 mg/kg (once daily for 8 days, i.p).
Group 4: Compound 1 (5 mg/kg, once daily for 8 days, 
i.p).
Group 5: Compound 1 (10 mg/kg, once daily for 8 days, 
i.p).
Behavioral experiments
Evaluation of static mechanical allodynia in PTX‑induced 
rats
The anti-allodynic effect of Compound 1 was measured at 
various intervals (i.e. on days 0, 2, 4, 6, and 8) using Von 
Frey (VF) filaments as described previously [21–23].
Evaluation of cold allodynia (acetone test)
Compound 1 (5 and 10 mg/kg) was investigated against 
PTX-induced cold pain (allodynia) by performing an ace-
tone test as described previously [24, 25]. In short, rats were 
habituated for 15 min in a transparent plastic box with a wire 
mesh floor. After that, a drop (0.05 mL) of acetone was put 
on the rat’s plantar skin surface using a syringe. The behav-
iors of rats (i.e. time taken by a rat while flinching, licking, 
withdrawing, and biting of hind paw) after the acetone spray 
was examined within 15 s and measured as paw withdrawal 
duration (PWD). A comparative increase in PWD (s) is con-
sidered to be a sign of neuropathic pain. Acetone was ejected 
three times on each hind paw and their average PWD was 
calculated for each rat.
Evaluation of thermal hyperalgesia
To evaluate further the analgesic effect of Compound 1 in 
PTX-induced rats, a hot plate test was performed according 
to the previously reported protocols [26–28]. The once-daily 
dosing of Compound 1 was examined for antihyperalgesic 
effect on days 0, 2, 4, 6, and 8.
Evaluation of tail‑flick latency (hot)
A hot tail immersion assay was performed to evaluate the 
central anti-nociceptive activity of Compound 1 as described 
previously [29, 30]. Briefly, the rat’s tail was immersed into 
52 °C water for 15 s (maximum), and the latency when the 
rat withdrew the tail was noted. The time taken by a rat to 
flick its tail from hot water was recorded as tail withdrawal 
latency (TWL). Each rat was exposed to three trials with a 
break of 5 min in between. The average of 3 trials was cal-
culated as latency for each rat.
Evaluation of tail‑flick latency (cold)
The cold-water tail-flick assay was performed to evaluate the 
cold hyperalgesia and antihyperalgesic effect of Compound 
1 by dipping the lower half of the rat’s tail into a beaker 
filled with cold water (0–4 °C) [29, 31]. After dipping the 
tail, the TWL was measured with a 15 s cut-off time. The 
test was studied 3 times at 5 min intervals to avoid tissue 
damage and the average was calculated. The antihyperal-
gesic effect was represented by the average of each latency 
(i.e. the comparatively longer latency was considered the 
antihyperalgesic effect) [32].
Fig. 1  A schematic representation of overall study plan
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Evaluation of motor performances
Assessment of Compound 1 treatment on motor perfor-
mances of rats was evaluated using a rotarod apparatus, 
which was rotating at a speed up to 40 rpm for 5 min. 
Before starting the experiment, all the rats were trained for 
4 days by placing them on a rotating drum with a maxi-
mum speed of 40 rpm as described previously [33, 34]. 
The rats which did not endure walking on the rotarod for 
more than 2 min were excluded. After that baseline trials 
were performed before any drug administration to start the 
experiment. Each rat underwent 3 trials. The latency of 
time to fall and the falling frequency over a 5-min period 
were measured. The same trials were repeated on days 2, 
4, 6, and 8, 1 h after treatment with Compound 1 or GBP.
Biochemical assays
RNA extraction and RT‑PCR
Total RNA was extracted from the L4-6 spinal cord seg-
ment of rats according to the manufacturer’s protocol 
using the TRI-reagent and the purity of the total RNA 
was determined using a UV spectrophotometer. Total RNA 
was transcribed to cDNA using a cDNA synthesis kit. The 
expressions of targeted genes like TNF-α, IL-1β, IL-6, 
iNOS, and COX-2 were determined (Table. 1). β-actin was 
incorporated as the housekeeping gene. Amplified prod-
ucts were isolated by the use of 1.5% agarose gel electro-
phoresis and visualized through a UV trans-illuminator. 
The expression level (A.U) was calculated [11, 35–38].
Nitric oxide (NO) determination
The production of NO in the spinal tissue was quantified 
using the Griess reagent assay according to the previously 
reported protocols [39–41].
Determination of antioxidant enzymes
The levels of antioxidants such as GSH, GST, and cata-
lase were measured according to the previously reported 
method [42, 43].
Lipid peroxidation assay (LPO)
LPO was estimated by measuring the MDA concentra-
tion in spinal tissue according to the previously reported 
method [44–46]. A microplate reader was used to measure 
the absorbance at 535 nm.
Pharmacokinetics and toxicokinetic analysis
An in-silico analysis was performed to determine the phar-
macokinetic behavior of Compound 1. The various phar-
macokinetics factors that were assessed include absorption, 
distribution, metabolism, excretion, the volume of distri-
bution, and plasma protein binding. The pharmacokinetic 
parameters were analyzed using Swiss target prediction and 
pK-CSM online server as reported previously [47]. Simi-
larly, the toxicokinetic analysis was performed to assess 
the harmful effect of Compound 1 against animals, tissue, 
and micro-organisms, and the maximum tolerated dose was 
established using online computational tools [47].
Statistical analysis
Data expressed as the mean ± SD. Two-way ANOVA was 
applied followed by Bonferroni’s post hoc test for the assess-
ment of statistical significance amongst various treated 
groups. Statistical analysis of the data was performed using 
Sigma-plot version 12.5. p” value < 0.05 was considered to 
be statistically significant.
Results
Effect of Compound 1 on static mechanical allodynia
Allodynia produced by administration of PTX was consid-
erably (p < 0.001) inhibited by treatment with Compound 
1 and GBP in a dose-dependent manner. The antiallodynic 
effect was indicated by increased paw withdrawal threshold 
(PWT) by treatment with Compound 1 when evaluated on 
Table 1  The sequences of PCR primers
Primer Sequence
IL-1β F- 5'-TGA TGA CGA CCT GCT AGT GTG-3°
R- 5'- TCC ATT GAG GTG GAG AGC TT-3°
IL-6 F- 5'-GGA GTT TGT GAA GAA CAA CT  3°
R- 5'- CTA GGG TTT CAG TAT TGC TC-3°
TNF-α F- 5'- ATG AGC ACA GAA AGC ATG ATC-3'
R- 5'-TAC AGG CTT GTC ACT CGA ATT-3'
iNOS F- 5'-CAC CAC CCT CCT TGT TCA AC-3'
R; 5'-CAA TCC ACA ACT CGC TCC AA-3'
COX-2 F- 5′-TGT ATG CTA CCA TCT GGC TTCGG-3’
R- 5’-GTT TGG AAC AGT CGC TCG TCATC-3’
β-actin F- 5′- CGT TGA CAT CCG TAA AGA CCTC-3';
R- 5'-TAG GAG CCA GGG CAG TAA TCT -3'
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the 2nd, 4th, 6th, and  8th day. The PWT (g) was remarkably 
high in the treatment groups as compared to the PTX group 
(Fig. 2a).
Effect of Compound 1 on cold allodynia
Cold allodynia in PTX-treated rats was significantly 
(p < 0.001) high as compared to the normal control groups 
as evident from the comparative rise in PWD (s). However, 
this increase in PWD was reduced by treatment with Com-
pound 1 and GBP (Fig. 2b).
Effect of Compound 1 on thermal hyperalgesia
Treatment with Compound 1 markedly (p < 0.001) lowered 
the hyperalgesic responses (paw licking and jumping) dose-
dependently in PTX-treated rats as denoted by increased paw 
withdrawal latency (PWL) in treatment groups (Fig. 2c).
Effect of Compound 1 on tail hot hyperalgesia
The hot tail immersion nociception is indicative of central 
nociception. Rats treated with PTX exhibited shortened 
TWL (s) as compared to the normal control. However, 
Compound 1 treatment markedly (p < 0.001) increased TWL 
(Fig. 2d).
Effect of Compound 1 on tail cold hyperalgesia
In PTX-treated rats, TWL was significantly reduced than 
normal animals indicating cold hyperalgesia. Compound 1 
daily treatment remarkably (p < 0.001) elevated this reduc-
tion in TWL showing its anti-neuropathic pain potential 
(Fig. 2e).
Effect of Compound 1 on motor activity
Motor coordination was assessed through a rotarod test. No 
abnormal effect was observed on motor activity after the 
treatment with Compound 1. However, GBP exhibited a 
significant motor deficit indicated from low rotarod latency 
time (sec) (Fig. 2f).
Effect of Compound 1 on inflammatory cytokines
The mRNA level of inflammatory cytokines in spinal 
cord tissues was analyzed using RT-PCR. A significant 
(p < 0.001) induction in the expression of these cytokines 
was observed in the PTX-treated group. However, treat-
ment with Compound 1 significantly (p < 0.001) lowered the 
expression of these cytokines as compared to the negative 
control group (Fig. 3b-d).
Fig. 2  Dose-dependent effect of Compound 1 in doses of 5 and 
10  mg/kg in PTX-induced rats. Compound 1 pretreatment inhibited 
PTX-induced (a) mechanical allodynia (b) cold allodynia (c) thermal 
hyperalgesia (d) tail thermal hyperalgesia (e) tail cold hyperalgesia 
and (f) motor activity. The data is displayed as the mean (n = 6) ± SD. 
ANOVA followed by a post hoc Bonferroni test was applied for com-
paring statistical differences between groups. *p ≤ 0.05, **p ≤ 0.01, 
and ***p ≤ 0.001 represent a statistically significant difference from 
the PTX-induced group. (###) indicates comparison to the normal 
control group
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Effect of Compound 1 on iNOS and COX‑2 mRNA 
expression levels
To further determine the inhibitory effect of Compound 
1 on inflammatory mediators, we evaluated the mRNA 
expression level of iNOS and COX-2 in the spinal cord. 
There was an up-regulation of iNOS and COX-2 mRNA 
expression after neuropathic pain induction which was 
significantly (p < 0.001) inhibited by treatment with Com-
pound 1 (Fig. 3e, f).
Effect of Compound 1 on antioxidants
The levels of antioxidants were significantly (p < 0.001) 
reduced in the PTX-treated group. However, Compound 1 
increased the level of these antioxidant proteins as shown 
in (Table. 2).
Effect of Compound 1 on nitric oxide (NO) 
production
The NO production was significantly (p < 0.001) increased 
in the PTX-treated group. Treatment with Compound 1 
remarkably (p < 0.001) inhibited the PTX-induced NO pro-
duction (Table. 2).
Effect of Compound 1 on LPO
PTX administration significantly (p < 0.001) elevated 
the MDA level. Compound 1 treatment showed a marked 
(p < 0.001) decrease in MDA level as compared PTX-treated 
group (Table. 2).
Pharmacokinetics and toxicokinetic analysis
The pharmacokinetic analysis of the compounds showed 
variable pharmacokinetic properties using online pKCSM 
software (http:// biosig. unime lb. edu. au/ pkcsm/ predi ction). 
Fig. 3  a Effect of Compound 1 treatment on mRNA expression level 
of (b) IL-1β (c) IL-6 (d) TNF-α (e) iNOS and (f) COX-2. The results 
are shown in a relatively arbitrary unit (A.U). The data is displayed 
as the mean (n = 6) ± SD. ANOVA followed by a post hoc Bonferroni 
test was applied for comparing statistical differences between groups. 
*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 represent a statistically sig-
nificant difference from the PTX-induced group. (###) indicates com-
parison to the normal control group
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The various properties that were predicted include drug-
like properties, physicochemical properties, lipophilicity, 
water solubility, and pharmacokinetic properties. Simi-
larly, the toxicokinetic analysis of the Compound 1 showed 
a good safety profile as shown in Table 3.
Discussion
PTX is an effective chemotherapeutic drug indicated in 
the treatment of breast, ovarian, lung, and bladder can-
cers. However, PTX-induced peripheral neuropathy is a 
Table 2  Effect of Compound 1 
on antioxidants, LPO and NO 
production in PTX-induced rat’s 
spinal tissue
The data is presented as the mean (n = 6) ± SD
(###) denotes comparison to normal control group
***p denotes comparison to PTX-induced group
Parameters Normal control PTX GBP (75 mg/kg) Compound 1 (10 mg/kg)
GSH concentration (µM) 14.47 ± 0.39 3.45 ± 0.28### 11.42 ± 0.39*** 10.90 ± 0.36***
GST concentration (µM) 38.92 ± 1.27 12.43 ± 1.38### 36.70 ± 1.14*** 36.25 ± 1.66***
Catalase activity (unit/µL) 11.6 ± 0.17 3.88 ± 0.09### 11.16 ± 0.09*** 11.03 ± 0.14***
MDA level (%) 10.68 ± 0.30 100 ± 2.86### 16.89 ± 1.68*** 18.01 ± 0.68***
NO production (µM) 7.61 ± 0.51 56.06 ± 6.56### 11.29 ± 1.90*** 11.64 ± 1.34***
Fig. 4  Graphical abstract representing anti-neuropathic pain activity of Compound 1 in PTX-induced neuropathic pain model
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major adverse effect and causes premature termination 
of cancer therapy. This adverse effect may persist up 
to several months even after discontinuation of therapy 
[7]. Current therapies have been associated with a wide 
spectrum of adverse effects that limit their satisfactory 
clinical use. It is important to identify novel drugs that 
effectively suppress neuropathic pain without attenuating 
their anticancer effects [2]. Numerous studies have shown 
the role of inflammatory cytokines, NO, COX-2, and oxi-
dative stress in the initiation and maintenance of neuro-
pathic pain [48–50]. Therefore, the drug that inhibits the 
release of inflammatory mediators might be the potential 
candidate to treat neuropathic pain. Previous findings have 
demonstrated that Compound 1 exhibited remarkable anti-
inflammatory and analgesic activities by suppressing the 
inflammatory mediator’s production. Therefore, keeping in 
view the previous promising therapeutic activities, Com-
pound 1 was further evaluated as an anti-neuropathic pain 
agent in the present study.
PTX significantly induced allodynia and hyperalgesia 
by increasing the rat’s plantar sensitivity to VF filaments, 
hot, and cold stimuli. The neuropathic pain produced by 
PTX administration was measured in the form of various 
pain parameters such as decreasing PWT, PWL, TWL, 
and increase in PWD [29]. However, these parameters of 
nociception were significantly improved by daily treatment 
with Compound 1 and GBP. Results from all the behavioral 
responses demonstrated the significant antiallodynic and 
antihyperalgesic activities of Compound 1. Furthermore, 
Compound 1 did not show any deteriorating effect on motor 
activity.
Inflammatory cytokines play a crucial role in neuropathic 
pain by increased hypersensitivity [1] and lead to excessive 
nociceptive transmission in the spinal cord [51]. The chemical 
mediators secreted all over the inflammatory process sensitizes 
the nociceptors that produce pain hypersensitivity resulting 
in hyperalgesia and allodynia [19]. PTX has been revealed 
to induce the expression of proinflammatory cytokines, such 
as IL-1 and TNF-α, in the rat spinal cord [52]. In the present 
study, PTX treatment considerably increased the expression 
of inflammatory cytokines in spinal tissues. These inflam-
matory cytokines were remarkably reduced by Compound 1. 
Similarly, the iNOS and COX-2 expression levels were also 
measured. The present study showed that Compound 1sig-
nificantly suppressed iNOS and COX-2 expressions as well 
as NO production.
It is well known that oxidative stress plays a vital role in 
neuropathic pain [2]. In the present study, PTX administra-
tion significantly lowered the level of endogenous antioxidants 
i.e., GSH, GST, and catalase, respectively. The results dem-
onstrated that Compound 1 exhibited a protective role against 
the PTX-induced oxidative stress by enhancing the level of 
antioxidants in spinal tissues while decreasing the MDA level. 
Additionally, the pharmacokinetic analysis using pK-CSM 
software showed that Compound 1 exhibits high GIT absorp-
tion, BBB permeability, and interaction with the cytochrome 
p450 system, and partial risk of toxicity.
Table 3  Pharmacokinetic and toxicokinetic analysis of the Compound 1
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Conclusion
In summary, the present study revealed that the compound 
possesses significant antiallodynic and antihyperalgesic 
activities in the well-known PTX-induced neuropathic pain 
model. Compound 1 markedly suppressed the levels of 
proinflammatory cytokines, iNOS, COX-2, and oxidative 
stress (Fig. 4). The pharmacokinetic analysis showed that 
Compound 1 exhibits good ADME properties. We suggest 
from the present study that Compound 1 might be a useful 
candidate for the treatment of neuropathic pain. Additional 
research is needed to confirm these results.
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